 COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responsesUgur Sahin (),
Alexander Muik,
Evelyna Derhovanessian,
Isabel Vogler,
Lena M. Kranz,
Mathias Vormehr,
Alina Baum,
Kristen Pascal,
Jasmin Quandt,
Daniel Maurus,
Sebastian Brachtendorf,
Verena Lörks,
Julian Sikorski,
Rolf Hilker,
Dirk Becker,
Ann-Kathrin Eller,
Jan Grützner,
Carsten Boesler,
Corinna Rosenbaum,
Marie-Cristine Kühnle,
Ulrich Luxemburger,
Alexandra Kemmer-Brück,
David Langer,
Martin Bexon,
Stefanie Bolte,
Katalin Karikó,
Tania Palanche,
Boris Fischer,
Armin Schultz,
Pei-Yong Shi,
Camila Fontes-Garfias,
John L. Perez,
Kena A. Swanson,
Jakob Loschko,
Ingrid L. Scully,
Mark Cutler,
Warren Kalina,
Christos A. Kyratsous,
David Cooper,
Philip R. Dormitzer,
Kathrin U. Jansen and
Özlem Türeci
Nature, 2020, vol. 586, issue 7830, 594-599 Abstract: Abstract An effective vaccine is needed to halt the spread of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic. Recently, we reported safety, tolerability and antibody response data from an ongoing placebo-controlled, observer-blinded phase I/II coronavirus disease 2019 (COVID-19) vaccine trial with BNT162b1, a lipid nanoparticle-formulated nucleoside-modified mRNA that encodes the receptor binding domain (RBD) of the SARS-CoV-2 spike protein1. Here we present antibody and T cell responses after vaccination with BNT162b1 from a second, non-randomized open-label phase I/II trial in healthy adults, 18–55 years of age. Two doses of 1–50 μg of BNT162b1 elicited robust CD4+ and CD8+ T cell responses and strong antibody responses, with RBD-binding IgG concentrations clearly above those seen in serum from a cohort of individuals who had recovered from COVID-19. Geometric mean titres of SARS-CoV-2 serum-neutralizing antibodies on day 43 were 0.7-fold (1-μg dose) to 3.5-fold (50-μg dose) those of the recovered individuals. Immune sera broadly neutralized pseudoviruses with diverse SARS-CoV-2 spike variants. Most participants had T helper type 1 (TH1)-skewed T cell immune responses with RBD-specific CD8+ and CD4+ T cell expansion. Interferon-γ was produced by a large fraction of RBD-specific CD8+ and CD4+ T cells. The robust RBD-specific antibody, T cell and favourable cytokine responses induced by the BNT162b1 mRNA vaccine suggest that it has the potential to protect against COVID-19 through multiple beneficial mechanisms. Date: 2020 Downloads: (external link) Related works: Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:586:y:2020:i:7830:d:10.1038_s41586-020-2814-7 Ordering information: This journal article can be ordered from DOI: 10.1038/s41586-020-2814-7 Access Statistics for this article Nature is currently edited by Magdalena Skipper More articles in Nature from Nature |
Is your work missing from RePEc? Here is how to contribute.
Questions or problems? Check the EconPapers FAQ or send mail to .
EconPapers is hosted by the
School of Business at Örebro University.